U.S. Consumer Finance Stock News

Wondering whether AngloGold Ashanti at around US$98.60 is still offering value after a strong run, or if most of the easy gains are already behind it. The stock has been volatile recently, with a 9.0% return over the last 7 days, a 2.8% decline over 30 days, a 15.2% return year to date, and a 136.0% return over the last year, alongside very large multi year gains of around 3x over 3 years and nearly 4x over 5 years. Recent coverage has focused on AngloGold Ashanti's position within the...

Ferguson Enterprises Q1 2026 headline numbers Ferguson Enterprises (FERG) opened fiscal Q1 2026 with revenue of about US$7.5b and basic EPS of US$2.13, setting a clear marker for how the business is starting the new financial year. The company has seen quarterly revenue move from roughly US$7.2b in Q1 2025 to about US$7.5b in Q4 2025 and then US$7.5b in Q1 2026. Basic EPS has shifted from US$1.74 to US$1.99 and then US$2.13 over the same periods, giving investors a view on how earnings are...

Why Regal Rexnord’s leadership change and upcoming earnings matter now Regal Rexnord (RRX) has drawn fresh attention after the board named Aamir Paul as incoming CEO by July 2026 and investors look ahead to Q1 results, where the market expects a return to revenue growth. See our latest analysis for Regal Rexnord. The recent 4.21% 1 day share price return and 24.84% 30 day share price return, on top of a 79.77% 1 year total shareholder return, suggest momentum has been building as investors...

Microchip Technology (MCHP) has drawn attention after a strong run over the past month, with the stock up 50.1%, alongside full year revenue of US$4.37b and a reported net loss of US$154.4m. See our latest analysis for Microchip Technology. Beyond the past month’s surge, Microchip Technology’s share price has a 7 day share price return of 16.9% and a year to date share price return of 51.4%. The 1 year total shareholder return of 114.7% points to strong recent momentum. If this kind of move...

JBT Marel (JBTM) has just put fresh numbers on the table for Q1 2026, coming off Q4 2025 revenue of about US$1.0 billion and basic EPS of US$1.02, against a trailing twelve month picture that includes a basic EPS loss of US$0.96 on US$3.8 billion of revenue. Over the past few quarters, the company has seen quarterly revenue move from US$453.8 million in Q3 2024 to US$854.1 million in Q1 2025 and then to roughly US$1.0 billion by Q4 2025. EPS swung from US$1.19 in Q3 2024 to a loss of US$3.35...

American Eagle Outfitters (NYSE:AEO) is shifting its supply chain to use Amazon's platform, marking a turn from its earlier anti Amazon positioning. The company is also launching a high profile marketing campaign featuring actor Sydney Sweeney. These moves reflect fresh efforts in e commerce operations and brand building that go beyond earlier discussions around earnings or valuation. American Eagle Outfitters, through its American Eagle and Aerie brands, competes in a crowded apparel and...

With NRG Energy last closing at US$150.64, this article looks at whether the stock is still priced for opportunity or already reflects most of its story, and what that may mean for you as an investor. The stock has returned 1.1% over the last 7 days and 0.6% over the last 30 days, with a year-to-date decline of 9.3% and a 28.4% return over the last year, alongside a very large gain over 5 years. Recent coverage has focused on NRG Energy's position within the US utilities sector and how its...

Venture Global (NYSE:VG) has taken a final investment decision on Phase 2 of its CP2 LNG project and secured project financing, reducing construction and cash flow risks. The company reached a commercial settlement with Edison related to Calcasieu Pass arbitration, addressing an outstanding legal dispute. Venture Global signed a new binding LNG purchase agreement with Vitol for five years starting in 2026. For investors watching US LNG developers, Venture Global sits at the intersection of...

If you are wondering whether Floor & Decor Holdings at around US$51 a share is attractively priced or a potential value trap, the starting point is understanding how the current market price lines up against different measures of value. The stock has recently moved 7.0% over the last week and 3.3% over the last month, while the year to date return sits at a 19.0% decline and the 1 year return at a 30.5% decline, which may catch the eye of investors weighing up risk and recovery...

Rogers (ROG) just posted first quarter results that met revenue expectations and beat non GAAP earnings estimates, then followed up with second quarter sales guidance that pointed to higher demand and supported a positive market reaction. See our latest analysis for Rogers. The recent results sit against a strong rebound in the stock, with a 30.98% 1 month share price return and a 50.24% year to date share price return, while the 1 year total shareholder return of 119.61% contrasts with...

Marzetti (MZTI) has just posted its Q3 2026 scorecard, with revenue of US$453.4 million and basic EPS of US$1.35, while the trailing twelve months show total revenue of about US$1.9 billion and EPS of US$6.40. Over recent quarters, revenue has ranged between US$457.8 million and US$518.0 million with quarterly EPS between US$1.18 and US$2.15. Taken together, this sets up a picture where headline growth expectations and the latest profit print now sit alongside a 9.1% net margin that frames...

If you are wondering whether Thermo Fisher Scientific at around US$472.95 is genuinely good value or just pricing in high expectations, the starting point is to look closely at what the current valuation is really saying. The stock has returned 1.4% over the last 7 days, a 3.1% decline over the last 30 days, a 20.2% decline year to date, but a 16.4% gain over the last year, which gives a mixed picture of sentiment and risk appetite over different time frames. Recent headlines have focused on...

Gartner (IT) has put fresh numbers on the board for Q1 2026, reporting revenue of US$1.5b and basic EPS of US$3.19 off net income of US$222.3m, setting the tone for how you might think about the rest of the year. Over recent quarters the company has seen revenue move between US$1.5b and US$1.8b, while quarterly EPS has ranged from US$0.47 to US$5.14, providing a clear view of how earnings power has fluctuated into this latest print. With trailing net margins now sitting well below last year’s...

Northrop Grumman (NYSE:NOC) has been selected by the Australian government to establish domestic solid rocket motor production. The agreement focuses on building local capability for advanced propulsion systems used in long range strike weapons. This marks an expansion of Northrop Grumman's solid rocket motor footprint outside the U.S. and deepens its role in allied defense supply chains. For investors tracking NYSE:NOC, this move extends the company's defense manufacturing reach into a key...

If you are wondering whether SoFi Technologies at around US$16.30 is starting to look expensive or still offers value, it helps to step back and look at what the recent price action and fundamentals are really saying. The stock has seen mixed returns, with a 5.0% move over the last 7 days, 0.2% over 30 days, a 40.6% decline year to date, and a 25.3% return over the past year. These shifts can change how investors think about both its growth potential and risk. Recent coverage has focused on...

If you are wondering whether Edwards Lifesciences at around US$83.20 still offers value, the key question is how its current price stacks up against what the business may be worth. The stock has returned 2.4% over the past week and 2.5% over the past month, with a 10.9% return over the last year but a year to date return of 2.5% decline and softer 3 year and 5 year returns of 6.4% and 4.9% declines. Recent headlines around Edwards Lifesciences have focused on its role in the broader medical...

Weis Markets has reported past first-quarter 2026 results showing sales of US$1,251.72 million and net income of US$27.85 million, alongside a reaffirmed quarterly dividend of US$0.34 per share payable on May 26, 2026. The strong year-over-year increase in earnings per share from US$0.73 to US$1.13 points to improved profitability despite only modest revenue growth. We’ll now look at how Weis Markets’ sharp earnings per share improvement shapes its investment narrative and potential...

Rambus (RMBS) has drawn fresh attention after launching a PCIe 7.0 Switch IP with Time Division Multiplexing, aimed at addressing bandwidth, latency, and scalability needs in AI, cloud, and high performance computing systems. See our latest analysis for Rambus. The PCIe 7.0 Switch IP news lands during a sharp upswing in Rambus’s share price, with a 1 day share price return of 10.20% and a 30 day share price return of 41.01%. The 1 year total shareholder return is very large, suggesting...

Novavax, Inc. has reported past first-quarter 2026 results showing revenue of US$139.51 million, down sharply from US$666.66 million a year earlier, and a net loss of US$9.49 million compared with prior net income of US$518.65 million. The swing from earnings per share of US$3.22 to a basic loss of US$0.06 highlights how quickly Novavax’s profitability profile has shifted as its business mix changes. Next, we’ll examine how this sharp year-on-year revenue drop and move into loss-making...

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...

Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations. This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments. The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners. For investors tracking Guardant Health...

Alkermes Q1 2026 earnings: setting the stage Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These...

Tango Therapeutics recently outlined leadership changes, including appointing Malte Peters as CEO and moving Barbara Weber to Executive Chair, alongside plans for pivotal trials and a pan-RAS supply agreement, while also granting equity awards to its new CFO and another employee under its 2023 Inducement Plan. These developments highlight how Tango’s evolving leadership structure and long-term incentive grants are being aligned with upcoming clinical milestones and partnership...

Fresh Del Monte Produce (FDP) opened 2026 with mixed momentum, coming off Q4 2025 revenue of US$1.0 billion and basic EPS of US$0.67 on net income of US$31.9 million, while trailing 12 month EPS sat at US$1.90 on net income of US$90.7 million from US$4.3 billion in revenue. Over recent quarters the company has seen quarterly revenue move between US$1.0 billion and US$1.2 billion, with basic EPS ranging from a loss of US$0.61 in Q3 2025 to a high of US$1.18 in Q2 2025, alongside trailing 12...